ArticleScientific reports2021
Prediction of sarcopenia using a battery of circulating biomarkers.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Comparative efficacy of different interventions on circulating factors in sarcopenia individuals: a systematic review and network meta-analysis.Aging clinical and experimental research · 2026Pooled it
- C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Biomarkers associated with lower limb muscle function in individuals with sarcopenia: a systematic review.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Changes in selected exerkines concentration post folk-dance training are accompanied by glucose homeostasis and physical performance improvement in older adults.Scientific reports · 2023Trial
- Current evidence and emerging therapeutic strategies for non-exercise interventions in sarcopenia associated with chronic obstructive pulmonary disease: a narrative review.Journal of thoracic disease · 2026Review
- Smoking quitting promotes neuromuscular and cartilage recovery in knee osteoarthritis.European journal of applied physiology · 2026Article
- Calprotectin and Sarcopenia in COPD: Biomarker, Bystander or Target?Journal of cachexia, sarcopenia and muscle · 2026Article
- Integration of patient-reported outcomes and myokine profiling for the detection of physical inactivity in COPD: an exploratory multicentre study.Scientific reports · 2026Article
- Metabolite biomarkers present in urine predict alterations in skeletal muscle associated with sarcopenia.Frontiers in aging · 2026Article
- Establishing Blood-Based Biomarkers for Sarcopenia: Current Challenges and Future Directions.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Associations of plasma Neurofilament light chain with sarcopenia and physical capacity in patients with Alzheimer's diseases.Acta neurologica Belgica · 2025Observational
- Plasma Extracellular Vesicles Biomarkers Linked to Lower Muscle Mass, Function and Physical Performance in Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- Comprehensive Insights into Sarcopenia in Dialysis Patients: Mechanisms, Assessment, and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2025Review
- Proteo-metabolomic insights for early dual physical and cognitive impairments: A search for biomarkers of healthy aging based on muscle-brain crosstalk.Aging cell · 2025Article
- Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit-Acquired Weakness: A Prospective Single-Center Cohort Study.Neurocritical care · 2025Observational
- State-of-the-art insights into myokines as biomarkers of sarcopenia: a literature review.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Pathophysiological mechanisms and emerging therapeutic strategies for muscle wasting: an integrative review.Frontiers in physiology · 2025Review
- Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets.Canadian journal of physiology and pharmacology · 2024Review
- Tracking the Plasma C-Terminal Agrin Fragment as a Biomarker of Neuromuscular Decline in 18- to 87-Year-Old Men.Molecular diagnosis & therapy · 2024Article
- Proteomics and machine learning in the prediction and explanation of low pectoralis muscle area.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not known. We recruited male healthy controls and patients with CHF and COPD (n = 81-87/group), aged 55-74 years. Sarcopenia was clinically identified based on hand-grip strength, appendicular skeletal muscle index and physical capacity as recommended by the European working group for sarcopenia. The serum levels of amino-terminal pro-peptide of type-III procollagen, c-terminal agrin fragment-22, osteonectin, irisin, fatty acid-binding protein-3 and macrophage migration inhibitory factor were significantly different between healthy controls and patients with CHF and COPD. Risk scores for individual biomarkers were calculated by logistic regressions and combined into a cumulative risk score. The median cutoff value of 3.86 was used to divide subjects into high- and low-risk groups for sarcopenia with the area under the curve of 0.793 (95% CI = 0.738-0.845, p < 0.001). A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.